Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).

Autor: Trukhin D; Day Patient Facility of Dispensary and Policlinic Department, Odessa Regional Oncological Dispensary, Odessa, Ukraine., Poddubskaya E; VitaMed, LLC, Moscow, Russia., Andric Z; Clinical Hospital Center, Bezanijska kosa Bezanijska kosa bb, Beograd, Serbia., Makharadze T; Ltd High Technology Hospital Medcenter, Batumi, Adjara, Georgia., Bellala RS; Queens NRI Hospital, Visakahapatnam, India., Charoentum C; Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Muang, Chiang Mai, Thailand., Yañez Ruiz EP; Oncology-Hematology Unit. Department of Internal Medicine. School of Medicine, Clinical Research Center SIM, University of the Frontera, Temuco, Chile., Fulop A; Orszagos Koranyi Pulmonologiai Intezet, VI. Tudobelosztaly, Budapest, Hungary., Hyder Ali IA; Respiratory Department, Hospital Pulau Pinang, George Town, Pinang, Malaysia., Syrigos K; Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, Athens, Greece., Katgi N; Dr. Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, Health Sciences University, Izmir, Yenisehir, Turkey., Lopez Chuken YA; Hospital Universitario 'Dr. Jose Eleuterio Gonzalez' (Centro Universitario contra el Cancer), Monterrey, Nuevo Leon, Mexico., Rumyana I; Plovid Department of Medical Oncology, Multiprofile Hospital for Active Treatment Central Onco Hospital OOD, Plovdiv, Bulgaria., Reyes-Igama J; Baguio General Hospital and Medical Center. Baguio city, Benguet, Philippines., Costamilan RC; Fundacao Universidade de Caxias do Sul, Instituto de Pesquisas Clinicas para Estudos Multicentricos, IPCEM, Caxias do Sul, Brazil., Del Campo García A; mAbxience Research S.L., Madrid, Spain. ana.delcampo@mabxience.com., Florez A; mAbxience Research S.L., Madrid, Spain., Paravisini A; mAbxience Research S.L., Madrid, Spain., Millan S; mAbxience Research S.L., Madrid, Spain.

Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2021 Jul; Vol. 35 (4), pp. 429-444. Date of Electronic Publication: 2021 Apr 29.